Synairgen and Pharmaxis’ Fibrosis Therapy Candidate Is Heading for Phase 1 Clinical Trial
Idiopathic Pulmonary Fibrosis, News
A potential pulmonary fibrosis therapy that Synairgen and Pharmaxis have been working on is heading for a Phase 1 clinical trial. The two created PXS-5382A as a treatment for idiopathic pulmonary fibrosis (IPF) and other ... Read more